64 related articles for article (PubMed ID: 37185057)
1. Development and validation of a urinary microRNA biomarker panel as a tool for early detection of prostate cancer in a Chinese population.
Zhang N; Wang J; Zhang S; Wu H; Li Z; Hu M
Biomarkers; 2023 Jun; 28(4):372-378. PubMed ID: 37185057
[TBL] [Abstract][Full Text] [Related]
2. The value of a three-microRNA panel in serum for prostate cancer screening.
Lin S; Sun C; Li R; Lu C; Li X; Wen Z; Ge Z; Chen W; Li Y; Li H; Lai Y
Int J Biol Markers; 2024 Mar; 39(1):70-79. PubMed ID: 37960876
[TBL] [Abstract][Full Text] [Related]
3. Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy.
Malla B; Aebersold DM; Dal Pra A
J Transl Med; 2018 Aug; 16(1):223. PubMed ID: 30103771
[TBL] [Abstract][Full Text] [Related]
4. Plasma MicroRNA Pair Panels as Novel Biomarkers for Detection of Early Stage Breast Cancer.
Fang R; Zhu Y; Hu L; Khadka VS; Ai J; Zou H; Ju D; Jiang B; Deng Y; Hu X
Front Physiol; 2018; 9():1879. PubMed ID: 30670982
[No Abstract] [Full Text] [Related]
5. Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis.
Moya L; Meijer J; Schubert S; Matin F; Batra J
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845775
[TBL] [Abstract][Full Text] [Related]
6. Investigating differential miRNA expression profiling using serum and urine specimens for detecting potential biomarkers for early prostate cancer diagnosis.
Hasanoğlu S; Göncü B; Yücesan E; Atasoy S; Kayalı Y; Özten Kandaş N
Turk J Med Sci; 2021 Aug; 51(4):1764-1774. PubMed ID: 33550766
[TBL] [Abstract][Full Text] [Related]
7. Detection of microRNAs expression signatures in vitreous humor of intraocular tuberculosis.
Chadalawada S; Rathinam SR; Lalitha P; Kannan NB; Devarajan B
Mol Biol Rep; 2023 Dec; 50(12):10061-10072. PubMed ID: 37906423
[TBL] [Abstract][Full Text] [Related]
8. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition.
Porzycki P; Ciszkowicz E; Semik M; Tyrka M
Int Urol Nephrol; 2018 Sep; 50(9):1619-1626. PubMed ID: 30014459
[TBL] [Abstract][Full Text] [Related]
9. Non‑invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles.
Koppers-Lalic D; Hackenberg M; de Menezes R; Misovic B; Wachalska M; Geldof A; Zini N; de Reijke T; Wurdinger T; Vis A; van Moorselaar J; Pegtel M; Bijnsdorp I
Oncotarget; 2016 Apr; 7(16):22566-78. PubMed ID: 26992225
[TBL] [Abstract][Full Text] [Related]
10. The value of a panel of circulating microRNAs in screening prostate cancer.
Sun C; Lu C; Li X; Li R; Wen Z; Ge Z; Chen W; Li Y; Sun S; Yang Q; Tao L; Li H; Lai Y
Transl Cancer Res; 2024 Feb; 13(2):686-698. PubMed ID: 38482417
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Validation of Novel microRNA Panel for Non-Invasive Prediction of Prostate Cancer.
Kumari S; Manoj A; Rungta S; Kumar M; Prasad G; Kumar D; Mahdi AA; Ahmad MK
Cureus; 2024 Apr; 16(4):e58207. PubMed ID: 38741808
[TBL] [Abstract][Full Text] [Related]
12. Prognostic microRNAs as biomarkers for prostate cancer.
Palanisamy H; Manoharan JP; Vidyalakshmi S
J Cancer Res Ther; 2024 Jan; 20(1):297-303. PubMed ID: 38554337
[TBL] [Abstract][Full Text] [Related]
13. Urinary exosomal miRNA signature of IgA nephropathy: a case-control study.
Shankar M; Shetty A; N S M; C G S; A K; Tennankore K
Sci Rep; 2023 Dec; 13(1):21400. PubMed ID: 38049447
[TBL] [Abstract][Full Text] [Related]
14. Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients.
Petersen PHD; Lopacinska-Jørgensen J; Høgdall CK; Høgdall EV
Mol Biol Rep; 2023 Dec; 50(12):10235-10247. PubMed ID: 37934368
[TBL] [Abstract][Full Text] [Related]
15. Screening of lung cancer serum biomarkers based on Boruta-shap and RFC-RFECV algorithms.
Yue G
J Proteomics; 2024 Jun; 301():105180. PubMed ID: 38663548
[TBL] [Abstract][Full Text] [Related]
16. miR-6805-5p as a biomarker of cisplatin-induced nephrotoxicity in patients with head and neck cancer.
Torso NG; Quintanilha JCF; Cursino MA; Pincinato EC; Loren P; Salazar LA; Lima CSP; Moriel P
Front Pharmacol; 2023; 14():1275238. PubMed ID: 38089043
[No Abstract] [Full Text] [Related]
17. Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer.
Dong L; Hu C; Ma Z; Huang Y; Shelley G; Kuczler MD; Kim CJ; Witwer KW; Keller ET; Amend SR; Xue W; Pienta KJ
Res Sq; 2024 Mar; ():. PubMed ID: 38585988
[TBL] [Abstract][Full Text] [Related]
18. Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer.
Shi W; Wartmann T; Accuffi S; Al-Madhi S; Perrakis A; Kahlert C; Link A; Venerito M; Keitel-Anselmino V; Bruns C; Croner RS; Zhao Y; Kahlert UD
Br J Cancer; 2024 Jan; 130(1):125-134. PubMed ID: 37950093
[TBL] [Abstract][Full Text] [Related]
19. A Three-Gene Classifier Associated With MicroRNA-Mediated Regulation Predicts Prostate Cancer Recurrence After Radical Prostatectomy.
Cheng B; He Q; Cheng Y; Yang H; Pei L; Deng Q; Long H; Zhu L; Jiang R
Front Genet; 2019; 10():1402. PubMed ID: 32117427
[TBL] [Abstract][Full Text] [Related]
20. Hyperglycemia and microRNAs in prostate cancer.
Russo V; Tamburrino L; Morselli S; Sani C; Baldi E; Sebastianelli A; Raspollini MR; Mongia A; Carradori V; Lallo E; Munnia A; Bisanzi S; Marchiani S; Visioli C; Rapi S; Serni S; Zappa M; Carozzi F; Peluso M
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38402304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
